Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Apr;45(4):506–512. doi: 10.1038/bjc.1982.86

A trial of nonspecific immunotherapy using systemic C. parvum in treated patients with Dukes B and C colorectal cancer.

R G Souter, P G Gill, P J Morris
PMCID: PMC2010994  PMID: 7041943

Abstract

In view of the relatively poor prognosis for patients after surgery for locally invasive colorectal cancer a trial of repeated systemic infusions of Corynebacterium parvum (CP) has been carried out. It is in this group of patients, with a high risk of recurrence from small residues of cancer left by the surgeon, that immunotherapy should have its optimum chance of success. A total of 92 patients were included in a randomized controlled study. The two groups were comparable in terms of tumour stage at presentation, operation performed and mean age of patients, but the control group had a preponderance of male patients. The study was carried out over 54 months. Treatment resulted in greater side effects than had been predicted, and as a result many patients could not be considered for inclusion.

Full text

PDF
506

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bull D. M., Leibach J. R., Williams M. A., Helms R. A. Immunity to colon cancer assessed by antigen-induced inhibition of mixed mononuclear cell migration. Science. 1973 Sep 7;181(4103):957–959. doi: 10.1126/science.181.4103.957. [DOI] [PubMed] [Google Scholar]
  2. Chare M. J., Webster D. J., Baum M. Clinical experience in the use of C. parvum in the treatment of locally advanced carcinoma of the breast. Dev Biol Stand. 1977 Apr 13;38:495–499. [PubMed] [Google Scholar]
  3. Fisher B., Rubin H., Sartiano G., Ennis L., Wolmark N. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. Cancer. 1976 Jul;38(1):119–130. doi: 10.1002/1097-0142(197607)38:1<119::aid-cncr2820380121>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  4. Fisher R. A. In vitro and in vivo effects of Corynebacterium parvum on lymphocyte transformation. Dev Biol Stand. 1977 Apr 13;38:461–466. [PubMed] [Google Scholar]
  5. GOLD P., FREEDMAN S. O. DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med. 1965 Mar 1;121:439–462. doi: 10.1084/jem.121.3.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gill P. G., Morris P. J., Kettlewell M. The complications of intravenous Corynebacterium parvum infusion. Clin Exp Immunol. 1977 Nov;30(2):229–232. [PMC free article] [PubMed] [Google Scholar]
  7. Gill P. G., Morris P. J. The survival of patients with colorectal cancer treated in a regional hospital. Br J Surg. 1978 Jan;65(1):17–20. doi: 10.1002/bjs.1800650105. [DOI] [PubMed] [Google Scholar]
  8. Hollinshead A. C., McWright C. G., Alford TC GLEW D. H., Gold P., Herbeman R. B. Separation of skin reactive intestinal cancer antigen from the carcinoembryonic antigen of Gold. Science. 1972 Sep 8;177(4052):887–889. doi: 10.1126/science.177.4052.887. [DOI] [PubMed] [Google Scholar]
  9. James K., Merriman J., Woodruff M. F., McCormick J. N., McBride W. H., Innes J., Horne N. W. Further studies on the serological effects of C. parvum immunotherapy in cancer patients. Dev Biol Stand. 1977 Apr 13;38:501–506. [PubMed] [Google Scholar]
  10. Li M. C., Ross S. T. Chemoprophylaxis for patients with colorectal cancer. Prospective study with five-year follow-up. JAMA. 1976 Jun 28;235(26):2825–2828. [PubMed] [Google Scholar]
  11. Lockhart-Mummery H. E., Ritchie J. K., Hawley P. R. The results of surgical treatment for carcinoma of the rectum of St Mark's Hospital from 1948 to 1972. Br J Surg. 1976 Sep;63(9):673–677. doi: 10.1002/bjs.1800630902. [DOI] [PubMed] [Google Scholar]
  12. Mcdonald J. S. The immunobiology of colorectal cancer. Semin Oncol. 1976 Dec;3(4):421–431. [PubMed] [Google Scholar]
  13. Nairn R. C., Nind A. P., Guli E. P., Davies D. J., Rolland J. M., McGiven A. R., Hughes E. S. Immunological reactivity in patients with carcinoma of colon. Br Med J. 1971 Dec 18;4(5789):706–709. doi: 10.1136/bmj.4.5789.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pihl E., Nairn R. C., Nind A. P., Muller H. K., Hughes E. S., Cuthbertson A. M., Rollo A. J. Correlation of regional lymph node in vitro antitumor immunoreactivity histology with colorectal carcinoma. Cancer Res. 1976 Oct;36(10):3665–3671. [PubMed] [Google Scholar]
  15. Sadler T. E., Castro J. E. The effects of Corynebacterium parvum and surgery on the Lewis lung carcinoma and its metastases. Br J Surg. 1976 Apr;63(4):292–296. doi: 10.1002/bjs.1800630410. [DOI] [PubMed] [Google Scholar]
  16. Scott M. T. Corynebacterium parvum as an immunotherapeutic anticancer agent. Semin Oncol. 1974 Dec;1(4):367–378. [PubMed] [Google Scholar]
  17. Valdivieso M., Mavligit G. M. Chemotherapy and chemoimmunotherapy of colorectal cancer. Role of the carcinoembryonic antigen. Surg Clin North Am. 1978 Jun;58(3):619–631. doi: 10.1016/s0039-6109(16)41543-4. [DOI] [PubMed] [Google Scholar]
  18. Vose B. M., Gallagher P., Moore M., Schofield P. F. Specific and non-specific lymphocyte cytotoxicity in colon carcinoma. Br J Cancer. 1981 Dec;44(6):846–855. doi: 10.1038/bjc.1981.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Whittaker M., Goligher J. C. The prognosis after surgical treatment for carcinoma of the rectum. Br J Surg. 1976 May;63(5):384–388. doi: 10.1002/bjs.1800630513. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES